Adaptimmune Therapeutics Stock (NASDAQ: ADAP) stock price, news, charts, stock research, profile.
Open | - |
Close | - |
Volume / Avg. | 3.00 / 1.78M |
Day Range | - - - |
52 Wk Range | 0.42 - 2.05 |
Market Cap | $255.75M |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 38 |
Short Interest | 4% |
Days to Cover | 4.97 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Adaptimmune Therapeutics (NASDAQ:ADAP) through any online brokerage.
Other companies in Adaptimmune Therapeutics’s space includes: Zura Bio (NASDAQ:ZURA), Cabaletta Bio (NASDAQ:CABA), Precigen (NASDAQ:PGEN), Kyverna Therapeutics (NASDAQ:KYTX) and TScan Therapeutics (NASDAQ:TCRX).
Adaptimmune Therapeutics has a consensus price target of $4.26.
The stock price for Adaptimmune Therapeutics (NASDAQ: ADAP) is $1 last updated September 20, 2024 at 6:50 PM EDT.
There are no upcoming dividends for Adaptimmune Therapeutics.
Adaptimmune Therapeutics’s Q3 earnings are confirmed for Wednesday, November 6, 2024.
There is no upcoming split for Adaptimmune Therapeutics.
Adaptimmune Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.